Physician profile
Mikhail Gorokhov
NPI 1922116599
$6,368.72
in general payments reported to CMS, 2019-2025
37 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,374 · 2020: $1,884 · 2021: $2,304 · 2022: $807.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,103.56 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $575.71 | 2019-2022 | |
| Amarin Pharma, INC. | $460.33 | 2019-2022 | |
| Allergan, INC. | $361.79 | 2019-2020 | |
| Lilly USA, LLC | $344.42 | 2020-2022 | |
| Amgen INC. | $307.96 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $298.15 | 2019-2021 | |
| Avanir Pharmaceuticals, INC. | $297.23 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $286.84 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $281.57 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $257.60 | 2019-2021 | |
| Novo Nordisk INC | $253.30 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $216.09 | 2019-2021 | |
| Biohaven Pharmaceuticals, INC. | $177.18 | 2021 | |
| Eisai INC. | $164.95 | 2020-2021 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $149.43 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $108.10 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $79.01 | 2020-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $73.33 | 2022 | |
| Glaxosmithkline, LLC. | $55.65 | 2020-2021 | |
| Nestle Healthcare Nutrition INC. | $54.49 | 2020-2021 | |
| Kaleo, INC. | $52.66 | 2019 | |
| Medicure Pharma INC. | $40.12 | 2021 | |
| Sanofi-Aventis U.S. LLC | $38.83 | 2020-2022 | |
| Otsuka America Pharmaceutical, INC. | $38.09 | 2021 | |
| Medline Industries LP | $35.71 | 2020-2021 | |
| Arbor Pharmaceuticals, INC. | $33.57 | 2019 | |
| Adlon Therapeutics L.P. | $32.82 | 2020-2021 | |
| Jazz Pharmaceuticals INC. | $27.95 | 2021 | |
| Vistapharm, INC. | $26.68 | 2021 | |
| Dexcom, INC. | $25.25 | 2022 | |
| Idorsia Pharmaceuticals US INC | $25.23 | 2022 | |
| Ironwood Pharmaceuticals, INC | $19.79 | 2020 | |
| Novartis Pharmaceuticals Corporation | $19.74 | 2020 | |
| Xeris Pharmaceuticals, INC. | $17.66 | 2021 | |
| Alfasigma USA, INC. | $14.79 | 2021 | |
| Medtronic USA, INC. | $13.14 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikhail Gorokhov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.